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ABSTRACT
Objective: The objective of this study was to investigate the effect of virgin coconut oil (VCO) and hydrolyzed VCO (HVCO) on lipid profile and liver 
enzymes in dyslipidemic rats.
Methods: VCO was hydrolyzed using lipase from Rhizomucor miehei (active on sn-1,3 position). Thirty male rats (150–200 g) were induced 
with 2 ml/kg body weight (BW) egg yolk and lard oil twice a day for 30 days. Rats were divided into six groups which were given with sodium 
carboxymethylcellulose 0.5%, atorvastatin, VCO (4 and 6 ml/kg BW), and HVCO (4 and 6 ml/kg BW). Lipid profile including total cholesterol (TC), 
triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol 
(VLDL-C), and liver enzymes including serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) were 
measured after 14 days of treatment.
Results: The results of this study show that VCO and HVCO improve lipid profile (decrease in TC, TG, LDL-C, and VLDL-C, but increase in HDL-C). VCO 
and HVCO also lower atherogenic index, TC/HDL-C ratio, LDL-C/HDL-C ratio, SGOT, and SGPT. Result shows that HVCO improves lipid profile and liver 
enzymes better than VCO does.
Conclusion: VCO and HVCO improve lipid profile in dyslipidemic rats, not atherogenic, and not toxic to the liver. HVCO causes better lipid profile 
improvement, especially with 6 ml/kg BW dosage.
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INTRODUCTION
Virgin coconut oil (VCO) is a high-quality product from the coconut tree 
and one of mainstay products in tropical countries. Basically, there are 
two kinds of coconut oil: VCO and typical coconut oil (refined, bleached, 
and deodorized/RBD oil). Both VCO and RBD oils contain a beneficial 
fatty acid which is medium chain fatty acid (MCFA), but VCO has 
another beneficial effect because of its natural manufacturing process, 
and hence, it still contains large amount of phytonutrients [1,2].
In 1953–1957, based on his studies, Ancel Keys gave statements about 
the atherogenicity of fats. He stated that saturated fats, including 
coconut oil, could increase total cholesterol (TC) while unsaturated fats 
decrease TC. In 1960s, unsaturated fat industries in the United States 
took advantage of these statements to promote their products. Not 
until 1990s, negative perspective on coconut oil was cleared because 
formerly it had not been known that coconut oil is different from other 
saturated fats [2,3].
VCO is composed mainly of medium chain triglyceride (MCT). In 
the body, MCT and long-chain triglyceride (LCT) are metabolized 
differently. MCT is hydrolyzed in the mouth and stomach by lingual 
lipase and gastric lipase, respectively. The hydrolyzed form of MCT 
which is 2-monoacylglycerol and MCFA is rapidly absorbed by the 
enterocytes into the portal vein and then directly enters the liver to 
be metabolized into energy, and hence, MCT does not increase blood 
triglyceride (TG). On the other hand, LCT is not digested in the mouth 
and stomach. LCT should first be emulsified by bile acid and then 
hydrolyzed by lipase in the intestine (pancreatic lipase), absorbed by 
the enterocytes, and undergo resynthesis into new TGs. The new TGs 
enter the lymph system as chylomicrons which then transported into 
the heart and circulation, and hence, LCT increases blood TG. Due to 
its rapid metabolism, MCT oils are beneficial in preventing and treating 
obesity. MCT oil unique physicochemical properties are also known to 
be beneficial for improving health condition in general and lipid profile 
in particular [4-8].
Studies about the effect of VCO on cardiovascular disease prevention 
and treatment have been reported in several studies [9-14]. However, 
the study about VCO and its enzymatic hydrolysis on cardiovascular 
disease prevention and treatment has not been reported yet. The 
objective of this study was to evaluate the beneficial effect of VCO and 




VCO (Palem Mustika®, Indonesia) was procured from the local market. 
All chemicals and reagents used in this work were of analytical grade 
unless otherwise stated. Tris HCl (molecular biology grade) was 
purchased from Vivantis Inc., USA. Sodium hydroxide, sodium sulfate 
anhydrous, and sodium carboxymethylcellulose were the products 
of Merck, Germany. Distilled water was purchased from Bratachem, 
Indonesia. n-Hexane was obtained from Macron Chemicals, USA. Lipase 
from Rhizomucor miehei (>20000 U/g; Cat. No: L4277) was purchased 
from Sigma-Aldrich, USA. Lard oil and quail egg yolk used to induce 
dyslipidemia in rats were obtained from the local market. Atorvastatin 
20 mg tablets were purchased from the local pharmacy.
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Enzymatic hydrolysis of VCO
About 30 g of oil was weighed into 250 ml Erlenmeyer flask, and then 
30 ml distilled water, 12.5 ml 0.063 M CaCl2, 25 ml buffer Tris-HCl 1 
M pH 8, and 3 ml lipase from R. miehei were added into the flask. The 
mixture was incubated at 50°C and stirred at 200 rpm for 10 min 
of every 1 h incubation time (10 h). At the end of incubation time, 
the mixture was transferred into the separating funnel, then 50 ml 
n-hexane was added, and extraction was done. The mixture was allowed 
to stand for some time until two layers were formed. The upper layer 
(n-hexane fraction) was separated as the first filtrate, while the bottom 
layer (water fraction) was extracted again with 50 ml of n-hexane. 
The mixture was then allowed to stand for some time and the upper 
layer formed was separated as the second filtrate. The first and second 
filtrates were mixed, and then 250 g sodium sulfate anhydrous was 
added to absorb the water residue. The combined filtrate was allowed 
to stand for 15 min, filtered, and the n-hexane was evaporated using the 
water bath to obtain hydrolyzed VCO (HVCO) [15-19].
Experimental design
The experiment was carried out on 30 male rats, weighing approximately 
150–200 g. Rats were housed in an air-conditioned room at 22–25°C, 
under 12-light/dark cycle, fed on basal diet and tap water ad libitum. 
Animals fed on a basal diet for 1 week acclimatization before starting 
the experiment. The protocol was approved by the Animal Research 
Ethics Committees of the Faculty of Mathematics and Natural Sciences, 
Universitas Sumatera Utara, Indonesia (bearing number: 881/KEPH-
FMIPA/2016). After acclimatization period, rats were fasted for 18 h 
and blood TC was measured using strip test. Then, rats were given with 
2 ml/kg BW quail egg yolk and lard oil twice a day. After 30 days of 
induction, blood TC of each rats was measured and rats with TC higher 
than 200 mg/dl were used for the test [20,21].
Rats were divided into six groups (five animals each) and were given: 
(1) Distilled water (control group), (2) 10 mg/kg BW of atorvastatin, 
(3) 4 ml/kg BW of VCO, (4) 6 ml/kg BW of VCO, (5) 4 ml/kg BW 
of HVCO, and (6) 6 ml/kg BW of HVCO, for 14 days. After the end of 
treatment, rats were fasted for 18 h and anesthetized with 70 mg/kg 
BW of ketamine intraperitoneally. Blood was collected directly from the 
heart and centrifuged for 10 min at 3000 rpm to obtain serum. Serum 
collected was then analyzed for lipid profile (TC, TG, and high-density 
lipoprotein cholesterol [HDL-C]) and liver enzymes including serum 
glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic 
transaminase (SGPT). Low-density lipoprotein cholesterol (LDL-C), 
very low-density lipoprotein cholesterol (VLDL-C), atherogenic index 
(AI), TC/HDL-C ratio, and LDL-C/HDL-C ratio were calculated using 
these following equations [12,21-23]:
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All data were statistically analyzed using one-way ANOVA followed by 
Tukey’s test using computerized SPSS package program (SPSS 17.0 
software for Windows). Results are expressed as mean±standard error 
and considered significantly different at p<0.05.
RESULTS
Blood TC before and after treatment
After dyslipidemia induction, rats were given with tested oils for 
14 days. The effect of VCO and HVCO on blood TC before induction, after 
induction (before treatment), and after 14 days treatment and the mean 
of TC decrease are shown in Table 1.
From Table 1, it is shown that TC level in all the groups decreases 
during the treatment. The lowest TC decrease is in rats given with 
distilled water (control group) which is 36.8 mg/dl, while the highest 
TC decrease is in rats given with atorvastatin 10 mg/kg BW and HVCO 
6 mg/kg BW. TC decrease in rats given with atorvastatin and HVCO 
6 ml/kg BW is not significantly different which are 223.8 mg/dl and 
223.2 mg/dl, respectively.
Effect on lipid profile after 14 days of treatment
The effect of VCO and HVCO on lipid profile in dyslipidemic rats after 
14 days of treatment is presented in Table 2.
In Table 2, it is shown that rats fed with distilled water have the 
highest TC, TG, LDL-C, and VLDL-C level and the lowest HDL-C level, 
while VCO and HVCO (both 4 and 6 ml/kg BW) show the otherwise. 
The results in this study also show that TG, LDL-C, and VLDL-C levels in 
rats fed with 6 ml/kg BW HVCO and 10 mg/kg BW atorvastatin are not 
significantly different (p>0.05), while the TC and HDL-C in both groups 
are significantly different (p<0.05).
Effect on AI, TC/HDL-C ratio, and LDL-C/HDL-C ratio
The effect of VCO and HVCO on AI, TC/HDL-C ratio, and LDL-C/HDL-C 
ratio on dyslipidemic rats is shown in Table 3.
Table 3 shows that rats fed with distilled water have the highest AI, 
while AI in rats fed with atorvastatin, VCO, and HVCO is not significantly 
different. It is shown that rats fed with 6 ml/kg BW HVCO has the lowest 
AI which is 0.97. This value does not differ significantly with the group 
fed with atorvastatin which is 1.62. The highest TC/HDL-C ratio and 
LDL-C/HDL-C ratio in this study are the groups fed with distilled water 
which are 9.00 and 7.12, respectively, while the lowest TC/HDL-C and 
LDL-C/HDL-C ratios are the groups fed with 6 ml/kg BW HVCO which 
are 1.98 and 0.74, respectively.
Effect on liver enzymes
The effect of VCO and HVCO on liver enzymes (SGOT and SGPT) in 
dyslipidemic rats is shown in Table 4.
From Table 4, it is shown that liver enzymes (SGOT and SGPT) in rats 
fed with atorvastatin, VCO, and HVCO are significantly lower than rats 
fed with distilled water.
DISCUSSION
In this study, rats were given with quail egg yolk and lard oil to induce 
dyslipidemia. Blood TC was shown to increase after induction for 
30 days. This is due to the high cholesterol content in quail egg yolk 
and saturated fats in lard oil. Egg, especially from the bird species, was 
one of the protein sources that has high nutrition value and functional 
properties. However, too much consumption of egg would cause health 
problem such as coronary heart disease due to its high cholesterol 
content in the yolk. Quail egg yolk has been shown to have a very 
high cholesterol content. Aziz et al. (2012) reported that the average 
cholesterol content in chicken, duck, and quail eggs was 7.65 mg/g yolk, 
10.36 mg/g yolk, was 16.05 mg/g yolk, respectively, which show that 
quail eggs had significantly higher concentration of cholesterol per 
gram of yolk. On the other hand, lard oil could also induce dyslipidemia 
due to its high content of long saturated fatty acids (myristic acid, 
palmitic acid, and stearic acid) and unsaturated fatty acid (oleic acid). 
Lard oil contains about 26–27% of palmitic acid, and more than 50% of 
it is on the sn-2 position which causes lard oil to be more atherogenic 
than other oils which is high in palmitic acid (e.g., palm oil). In addition, 
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a high content of oleic acid (~40%) in lard oil has also been reported to 
elevate blood TG level [21,24-27].
In the present study, VCO and HVCO significantly decreased blood TC 
in dyslipidemic rats. The effect of VCO and HVCO to decrease TC level 
could be due to the unique physicochemical properties of fatty acids 
contained in VCO and its hydrolyzed form. VCO contains more than 
40% lauric acid which is one of the MCFAs. Oil which composed of 
MCFA (MCT oil) is metabolized in a different way than LCT oil which 
composed of LCFA. MCT is hydrolyzed in the mouth and stomach and 
then metabolized rapidly in the liver to produce energy. MCT does not 
increase blood TG level, and hence, it does not accumulate in adipose 
tissue. In addition, MCFA is not converted into lipoprotein which 
circulates in the blood like its counterpart LFCA [4,9,26].
In this study, the group fed with 6 ml/kg BW HVCO has the lowest TC 
and LDL-C levels but the highest HDL-C levels of all groups. However, 
TG and VLDL-C levels in group fed with 6 ml/kg BW are higher than the 
group fed with 4 ml/kg BW VCO. This may be due to the higher MCFA 
intake in the group fed with 6 ml/kg BW HVCO that exceeds caloric 
needs. Blood lipids are secreted from the intestine to blood circulation 
as chylomicrons and from the liver to circulation as VLDL. Both 
lipoproteins transport one molecule of apolipoprotein (apo) which is 
either B48 or B100. LCFA, such as oleic acid and palmitic acid, generally 
stimulates apoB secretion and increases intracellular TG, while MCFA 
inhibits apoB and TG secretion. Although MCFA could decrease TG 
secretion when consumed in small doses, excessive consumption of 
MCFA more than the caloric needs could increase de novo lipogenesis. 
This causes high TG secretion which then increases blood TG [25].
This study also reveals that rats fed with VCO and HVCO have higher 
TC level than rats fed with atorvastatin does. Although VCO and HVCO 
increase TC level, they also improve the lipid profile by increasing the 
HDL-C level. HDL-C is “the good cholesterol” because it has been known 
as a free radical scavenger which is able to prevent beta-lipoprotein 
peroxidation. High levels of HDL-C have been considered as a good 
indicator of a healthy heart. HDL-C below 40 mg/dl is considered as 
major risk factor of cardiovascular disease, whereas HDL-C higher than 
60 mg/dl is considered optimal [7,21,28].
Table 1: Effect of VCO and HVCO on blood TC
Group TC (mg/dl) Treatment TC after 14 days of treatment TC decrease (mg/dl)
Before induction After induction
1 98.6±3.9 386.2±3.8 Distilled water 349.4±5.6 36.8±6.5a
2 99.4±5.1 353.6±12.8 Atorvastatin 129.8±3.1 223.8±14.8b
3 95.6±5.7 336.6±8.2 VCO 4 ml/kg BW 226.2±3.1 110.4±6.9c
4 100.4±3.4 361.6±5.5 VCO 6 ml/kg BW 201.4±6.4 160.2±10.9d
5 95.8±5.4 333.8±8.4 HVCO 4 ml/kg BW 195.4±6.2 138.4±8.3c,d
6 97.8±5.9 376.8±7.7 HVCO 6 ml/kg BW 153.6±4.4 223.2±5.9b
Means±SE in each column with different superscript letters differ significantly at P<0.05 for n=5 observations. TC: Total cholesterol, VCO: Virgin coconut oil, HVCO: 
Hydrolyzed virgin coconut oil, SE: Standard error, BW: Body weight
Table 2: Effect of VCO and HVCO on lipid profile in dyslipidemic rats after 14 days of treatment
Treatment Lipid profile (mg/dl)
TC TG HDL-C LDL-C VLDL-C
Distilled water 349.4±5.5a 174.4±21.1a 39.0±1.7a 275.5±4.0a 34.9±4.4a
Atorvastatin 129.8±3.1b 86.8±8.4b,c 50.2±2.5b 62.2±3.2b 17.4±1.7b,c
VCO 4 ml/kg BB 226.2±3.1c 59.2±2.5c 72.6±1.1c 141.8±2.7c 11.8±0.5c
VCO 6 ml/kg BB 201.4±6.4d 122.0±12.9b 70.2±2.4c 106.8±5.7d 24.4±2.6b
HVCO 4 ml/kg BB 195.4±6.2d 70.8±10.7b,c 77.4±1.2c 103.8±5.6d 14.1±2.1b,c
HVCO 6 ml/kg BB 153.6±4.4e 81.0±4.4b,c 78.0±1.2c 59.4±4.1b 16.2±0.9b,c
Means±SE in each column with different superscript letters differs significantly at P<0.05 for n=5 observations. TC: Total cholesterol, VCO: Virgin coconut oil,  
HVCO: Hydrolyzed virgin coconut oil, SE: Standard error, TG: Triglyceride, LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein cholesterol,  
VLDL-C: Very low-density lipoprotein cholesterol
Table 3: Effect of VCO and HVCO on AI, TC/HDL-C ratio, and LDL-C/HDL-C ratio on dyslipidemic rats
Treatment AI TC/HDL-C ratio LDL-C/HDL-C ratio
Distilled water 8.01±0.32a 9.00±0.32a 7.12±0.27a
Atorvastatin 1.62±0.16b,c 2.62±0.17b,c 1.28±0.12b,c
VCO 4 ml/kg BW 2.12±0.47b 3.12±0.04c 1.94±0.05d
VCO 6 ml/kg BW 1.88±0.72b 2.90±0.07c 1.50±0.55c,d
HVCO 4 ml/kg BW 1.53±0.11b,c 2.52±0.12b,c 1.34±0.93c
HVCO 6 ml/kg BW 0.97±0.69c 1.98±0.06b 0.74±0.75b
Means±SE in each column with different superscript letters differs significantly at P<0.05 for n=5 observations. VCO: Virgin coconut oil, HVCO: Hydrolyzed virgin 
coconut oil, SE: Standard error, LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein cholesterol, BW: Body weight, AI: Atherogenic index
Table 4: Effect of VCO and HVCO on liver enzymes in 
dyslipidemic rats
Treatment SGOT (U/L) SGPT (U/L)
Distilled water 192.2±4.6a 100.8±4.8a
Atorvastatin 123.4±7.3b 79.4±2.8b
VCO 4 ml/kg BW 122.0±4.2b 72.8±4.5b
VCO 6 ml/kg BW 153.0±4.2c 68.2±2.1b,c
HVCO 4 ml/kg BW 95.0±3.5d 68.8±3.7b,c
HVCO 6 ml/kg BW 172.0±2.3c 56.6±1.4c
Means±SE in each column with different superscript letters differs significantly 
at P<0.05 for n=5 observations. VCO: Virgin coconut oil, HVCO: Hydrolyzed 
virgin coconut oil, SE: Standard error, SGOT: Serum glutamic oxaloacetic 
transaminase, SGPT: Serum glutamic pyruvic transaminase
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Besides other lipid profile parameters, AI is also one of the dyslipidemic 
atherogenic markers which is better than TC to predict the risk of 
cardiovascular disease. In this study, it is shown that AI in the group 
fed with 6 ml/kg BW HVCO does not differ significantly with group fed 
with atorvastatin. It means that 6 ml/kg BW HVCO could lower the risk 
of cardiovascular disease and has the similar effect as atorvastatin does 
[29]. Other markers for predicting cardiovascular risk are TC/HDL-C 
and LDL-C/HDL-C ratios. Both ratios in all groups have significantly 
lower values than group fed with distilled water. This shows that 
VCO and HVCO are effective in decreasing the risk of coronary artery 
disease, especially HVCO with dosage of 6 ml/kg BW. TC/HDL-C ratio 
and LDL-C/HDL-C ratio have been known as better predictors for the 
risk of coronary artery disease rather than TC, LDL-C, or HDL-C alone 
because the latter would ignore other dyslipidemic component such 
as TG elevation. Some studies show that the risk of coronary artery 
disease increases at the value of more than 4 for TC/HDL-C ratio and 
2.5 for LDL-C/HDL-C ratio [30,31].
Alteration in liver enzymes is an early marker for the tissue damage 
by toxic substances or disease conditions. SGOT and SGPT are liver 
enzymes that occur during hepatic cells damage [10]. In this study, it 
is shown that rats fed with VCO and HVCO significantly decrease SGOT 
and SGPT levels in dyslipidemic rats. This suggests that VCO and HVCO 
are not toxic to the liver.
CONCLUSION
From this study, it can be concluded that VCO and its hydrolyzed form 
are shown to significantly decrease serum TC, LDL-C, VLDL-C, TG levels, 
AI, TC/HDL-C ratio, LDL-C/HDL-C ratio, and liver enzymes (SGOT and 
SGPT) while increase HDL-C level in dyslipidemic rats. HVCO is also 
shown to have the most effective antidyslipidemic effect.
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